Advances in tumor vascular growth inhibition

• Keyong Zhang ^[1] ; Yuanyuan Shi ^[1] ; Ze Jin ^[1] ; Jian He ^[1]
  1. [1] State Key Laboratory of Targeting Oncology, National Center for International Research of Bio‑Targeting Theranostics, Guangxi Key Laboratory of Bio‑Targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning 530021, Guangxi, China
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 26, Nº. 9, 2024, págs. 2084-2096
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Tumor growth and metastasis require neovascularization, which is dependent on a complex array of factors, such as the production of various pro-angiogenic factors by tumor cells, intercellular signaling, and stromal remodeling. The hypoxic, acidic tumor microenvironment is not only conducive to tumor cell proliferation, but also disrupts the equilibrium of angiogenic factors, leading to vascular heterogeneity, which further promotes tumor development and metastasis. Anti-angiogenic strategies to inhibit tumor angiogenesis has, therefore, become an important focus for anti-tumor therapy. The traditional approach involves the use of anti-angiogenic drugs to inhibit tumor neovascularization by targeting upstream and downstream angiogenesis-related pathways or pro-angiogenic factors, thereby inhibiting tumor growth and metastasis. This review explores the mechanisms involved in tumor angiogenesis and summarizes currently used anti-angiogenic drugs, including monoclonal antibody, and small-molecule inhibitors, as well as the progress and challenges associated with their use in anti-tumor therapy. It also outlines the opportunities and challenges of treating tumors using more advanced anti-angiogenic strategies, such as immunotherapy and nanomaterials